ClinicalTrials.gg
Not yet recruitingNCT07824206Updated Sep 17, 2026

Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional Blunting

A Phase 4 interventional study of lumateparone 42 mg once daily and lumateparone in Blunted Emotion in Major Depressive Disorder, sponsored by Future Options Research, LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Future Options Research, LLC · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Planned enrollment
943rd of 1,323
30 · median 70
Started
2026
with 81 others
Phase 4
189 of 1,500
11 open now
Primary completion
2028-01
later than 153 of 258 live
Registered
1,486th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 943rd largest by planned enrollment of the 1,323 interventional ones that give a count, is one of 82 that started in 2026, is one of 189 in phase 4, reaches primary completion later than 153 of the 258 other live ones, and was the 1,486th registered.

Depressive Disorder, Major

3,047 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether or not adding lumateparone to current antidepressant treatment in adults with major depressive disorder experiencing blunted emotion will reduce or eliminate the blunted emotion as rated by the Oxford Depression Questionnaire.

Read the detailed description

Adults with Major Depressive Disorder who report blunted emotion that is evidenced by responses on the Oxford Depression Questionnaire will add lumateparone to their current treatment once daily for 8 weeks. Primary endpoint will be change fom baseline to week 8 on the Oxford Depression Questionnaire (ODQ). Secondary endpoints will be change from baseline to week 8 on CGI-I and CGI-S as well as change from baseline to week 8 on quality of life as measured by Q-LES-Q-SF.

03

Conditions studied

  • Blunted Emotion in Major Depressive Disorder

Keywords

  • Blunted emotion in Major Depressive Disorder
  • MDD
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Diagnosis of major depressive disorder documented in the medical record and confirmed through evaluation by the Principal Investigator using the M.I.N.I., Oxford Depression Questionnaire score of > 50 (substantial emotional blunting), Response of "yes" to the "gold standard" standardized screening question on emotional blunting developed by Price et al(2012): "Emotional effects vary, but may include, for example, feelingemotionally 'numbed' or 'blunted' in some way; lacking positive emotions or negative emotions; feeling detached from the world around you; or 'just not caring' about things you used to care about. Have you experienced such emotional effects during the last 6 weeks?" -

Exclusion Criteria: Concomitant antipsychotics, Concomitant inhibitors of , Concomitant use of cannabis, Moderate to severe hepatic impairment, Primary diagnosis other than major depressive disorder

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Lumateparone

    Investigation of addition of lumateparone for blunted emotion

    Drug: lumateparone 42 mg once daily · Drug: lumateparone

Interventions

  • Druglumateparone 42 mg once daily

    lumateparone 42 mg once daily added to current antidepressant treatment

  • Druglumateparone

    Lumateparone

This study also gives Lumateperone. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change from baseline to week 8 in Oxford Depression Questionnaire score

    Time frame: 8 weeks

07

Study locations

1 site
  • Future Options Research
    State College, Pennsylvania 16801, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2028, 16 months later.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 16 months is below that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2026
First posted
Sep 17, 2026
StartEst.
Sep 2026
Primary completionEst.
Jan 2028
CompletionEst.
Mar 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824206
Lead sponsor
Future Options Research, LLC
Collaborators
Johnson & Johnson
Responsible party
Erin Crown (Owner/Principal Investigator, Future Options Research, LLC) — Principal investigator
First posted
Sep 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Clinical Coordinator
Contact
info@futureoptionsresearch.com
814-237-0001 ext. 137
Erin Crown, PA-C, CAQ-Psychiatry
principal investigator · Future Options Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion